Sleep Solutions Newswire

Comprehensive Real-Time News Feed for Sleep Solutions.

Results 1 - 20 of 128 in Sleep Solutions

  1. Horizon Pharma Q1 Mixed, Settles Suit With PerrigoRead the original story w/Photo

    Friday May 8 | Investor's Business Daily

    Horizon's earnings excluding one-time items rose 62% over the year-earlier quarter to 21 cents a share, in line with analyst consensus, according to Thomson Reuters. Sales jumped 118% to $113.1 million, about $9 million above the Street's average estimate.


  2. Abbott May Be Hunting for M&A With Cash Reaped From Mylan's Three-Way TussleRead the original story

    Thursday May 7 | BioSpace

    The ongoing three-way bid tussle among Mylan NV , Teva Pharmaceuticals Industries Ltd , and Perrigo Company plc is serving to make all three parties richer, along with a surprising outsider: Abbott Laboratories , the biggest shareholder at Mylan. The market is now ripe with speculations on how the healthcare giant may deploy all its newly piled up cash, and acquisitions seem to be the most likely answer.


  3. John Paulson Increases Stake In Mylan To 4.5% Amid Teva BidRead the original story w/Photo

    Thursday May 7 | Seeking Alpha

    John Paulson bought the additional seven million shares of Mylan on April 30 . Paulson's hedge fund, Paulson & Co., increases its stake during a time in which Mylan faces a possible merger with Perrigo Company or a takeover by Teva Pharmaceuticals .


  4. Zacks Downgrades Perrigo Company PLC to SellRead the original story

    Wednesday May 6 |

    Zacks' analyst wrote, "Continued lackluster performance of Perrigo's Nutritionals and API segments is concerning. Meanwhile, CHC segment sales have been underperforming.


  5. Analyst: Mylan Shareholders Might Get Convinced By Vigodman LetterRead the original story

    Thursday Apr 30 | Benzinga

    Teva Pharmaceutical Industries Ltd. 's letter to Mylan NV suggests "much more commitment to pursuing a deal than we previously thought," an analyst said Thursday. Oppenheimer's Akiva Felt maintained an Outperform rating and $77 target on Teva and said the letter makes "an indirect but persuasive appeal to Mylan's shareholders."


  6. Mylan Raises Perrigo Bid, But Perrigo Still Says NoRead the original story w/Photo

    Wednesday Apr 29 | Investor's Business Daily

    Based on Mylan's share price on April 8, when it first proposed buying Perrigo, this most recent offer comes out to $232.23 per Perrigo share, or $35.6 billion. Perrigo, however, has been arguing that Mylan's stock price has been driven up by speculation that it would be bought by Since Teva has made clear that it's not interested in Perrigo, either inside or outside of Mylan, Perrigo considers the "real" Mylan stock price to be 55.31, which is where it closed before the Teva acquisition rumors started on March 10. "This morning we caught up with TEVA IR for a recap on the company's recent investor meetings with MYL shareholders," he wrote.


  7. Perrigo rejects Mylan's raised offerRead the original story

    Wednesday Apr 29 | Vallejo News

    Mylan NV boosted its cash-and-stock offer to buy Perrigo Co Plc to $34.10 billion , a bid that was swiftly rejected. Mylan's pursuit of Perrigo, a major producer of over-the-counter drugs, is widely seen as an attempt to fend off a $40 billion offer from Teva Pharmaceutical Industries Ltd , the world's biggest maker of generic drugs.


  8. Exclusive - Perrigo expected to reject Mylan's latest offer: sourceRead the original story

    Wednesday Apr 29 | Vallejo News

    Generic drugmaker Perrigo Company Plc > is expected to reject the latest offer made on Wednesday by Mylan NV , according to a person familiar with the matter. Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share under Mylan's latest offer.


  9. Mylan says Teva offer too low criticizes stock, growth prospectsRead the original story w/Photo

    Monday Apr 27 | Vallejo News

    Mylan NV rejected Teva Pharmaceutical Industries Ltd's $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed "high-risk" Teva stock. Teva, the world's biggest maker of generic drugs, quickly responded to Mylan's refusal with word that it was "fully committed" and would move forward with the $82 per share cash and stock offer.


  10. B. Riley Increases Perrigo Company PLC Price Target to $195.00Read the original story

    Saturday Apr 25 |

    The firm currently has a "buy" rating on the stock. B. Riley's price target indicates a potential upside of 1.09% from the stock's previous close.


  11. Worst Performing Industries For April 24, 2015Read the original story

    Friday Apr 24 | Benzinga

    The Dow dropped 0.01 percent to 18,056.49, while the NASDAQ composite index climbed 0.71 percent to 5,092.17. The broader Standard & Poor's 500 index gained 0.17 percent to 2,116.60.


  12. Mylan Chooses Its Own AdventureRead the original story w/Photo

    Apr 23, 2015 | Seeking Alpha

    Mylan announced that Mylan has made a proposal to acquire Perrigo Company plc under which Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for each Perrigo share. It is reasonable to expect MYL to bump their offer to at least $225 per share of PRGO.


  13. Don't Cash In On Perrigo Yet, Upside Still PossibleRead the original story w/Photo

    Apr 22, 2015 | Seeking Alpha

    Joe Papa believes strongly in his company's future growth opportunities, and he also believes that the Mylan offer significantly undervalues the Perrigo. We recommend a sell for Perrigo Company with two triggers based on the possible scenarios.


  14. 's M&A Chatter for Wednesday April 22, 2015Read the original story w/Photo

    Apr 22, 2015 | Benzinga

    The Rumor : Shares of Perrigo rose Wednesday, following a a report from CNBC's David Faber, that Mylan would submit a new bid for Perrigo. On Tuesday, Perrigo's Board unanimously rejected the $205.00 per share offer from Mylan, indicating that it substantially undervalues the company and is not in the best interests of shareholders.


  15. Perrigo's Rejection Of Offer Gives Mylan 5 Strategy OptionsRead the original story w/Photo

    Apr 21, 2015 | Seeking Alpha

    Last Friday, Mylan issued a press release that stated its desire to not engage in a merger with Teva Pharmaceuticals but to rather focus on its pursuit of Perrigo. This latest development puts Mylan in an interesting position and the firm has five main strategies that it could pursue from here.


  16. Teva Offers $40 Bil For Mylan; Perrigo Rejects MylanRead the original story

    Apr 21, 2015 | Investor's Business Daily

    But consensus on Wall Street said that price will have to go higher. proposal, half cash and half stock, would create a giant in the generic and specialty drug space with some $30 billion in annual revenue.


  17. Perrigo Board Rejects Buyout OfferRead the original story w/Photo

    Apr 21, 2015 | WSJM-AM Saint Joseph

    The board of directors of a major West Michigan pharmaceutical maker is turning aside an unsolicited buyout offer. Perrigo Company's board called the offer by British-based Mylan NV "substantially" undervalued and adds it is not in the best interests of shareholders.


  18. Perrigo rejects $205/share bid from MylanRead the original story

    Apr 21, 2015 | Vallejo News

    Dublin-based Perrigo Company Plc said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV , saying the bid substantially undervalued the company. Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros acquisition of Omega Pharma and new products that are expected to generate about $1 billion in revenue.


  19. Abbott Labs Reports First Quarter Earnings On Wednesday And Here Are My ThoughtsRead the original story w/Photo

    Apr 20, 2015 | Seeking Alpha

    I anticipate the company to talk about the currency exchange headwinds it faced in the quarter, but it will probably not have much effect on the stock. As the first calendar quarter came to an end, we saw the healthcare sector of the market move up a lot as measured by the Healthcare ETF while the market overall was relatively flat .


  20. Perrigo Company PLC Receives Average Rating of "Buy" from BrokeragesRead the original story

    Apr 20, 2015 |

    Perrigo Company PLC has received a consensus recommendation of "Buy" from the thirteen ratings firms that are currently covering the stock, AR Network reports . Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company.